The latest update is out from Avidity Biosciences Inc (RNA).
Avidity Biosciences, Inc. is set to discuss groundbreaking results from the MARINA-OLE™ trial on March 4, 2024, showcasing the effectiveness of del-desiran (AOC 1001) in reversing disease progression in myotonic dystrophy type 1 (DM1) patients. This promising data, highlighting improvements in myotonia, muscle strength, and daily activities, will be shared during an investor event and through a live webcast. In light of these findings, Avidity is preparing to launch the Phase 3 HARBOR™ trial, continuing to explore the therapeutic potential of del-desiran.
For detailed information about RNA stock, go to TipRanks’ Stock Analysis page.
